Published online Sep 15, 2021. doi: 10.4251/wjgo.v13.i9.1196
Peer-review started: February 6, 2021
First decision: May 8, 2021
Revised: June 1, 2021
Accepted: July 19, 2021
Article in press: July 19, 2021
Published online: September 15, 2021
Processing time: 215 Days and 17.2 Hours
Neoadjuvant chemoradiotherapy (Neo-CRT) is the current standard strategy for treatment of locally advanced rectal cancer (LARC). However, it delays the administration of optimal chemotherapy and increases toxicity.
This meta-analysis aimed to compare the feasibility and efficacy of neoadjuvant chemotherapy (Neo-CT) vs Neo-CRT for treatment of LARC.
To the best of our knowledge, this is the first meta-analysis to compare the efficacy and safety of Neo-CT without radiation vs Neo-CRT for rectal cancer patients, which included 19 randomized control trials or cohort studies published up to September 30, 2020.
The hazard ratio of overall survival and the risk ratio for the pathological complete response, the sphincter preservation rate, and treatment-related adverse events were analyzed.
The results of this study showed that Neo-CT decreased the incidences of anastomotic fistula and temporary colostomy and increased the sphincter preservation rate. Meanwhile, there was no significant difference in overall survival, the tumor downstaging rate, overall complications, urinary complications, and pathological complete response rates.
Neo-CT was effective for treatment of LARC, especially to lower the incidences of anastomotic fistula and temporary colostomy and increase the sphincter preservation rate as compared to Neo-CRT and could have the potential to provide an alternative to CRT for LARC.
All in all, owing to the negligible heterogeneity of every endpoint and the inclusion of only high-quality studies, these preliminary results suggested that the combination of full-dose Neo-CT without radiation presented a new neoadjuvant treatment option for LARC.